Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Key FDA decisions are expected to face delays.
The Titan CD8-guiding technology seems to have spawned a new variant.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
